Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

News >

Adjuvant Care at High-Volume Centers Shows Improved Survival in Pancreatic Cancer

Greg Kennelty
Published: Sunday, Mar 06, 2016

James L. Abbruzzese, MD

James L. Abbruzzese, MD

Patients with pancreatic cancer who were treated at high-volume centers had a 16-month improvement in overall survival versus those who were treated at community medical centers, according to findings from a study presented at the 2016 Gastrointestinal Cancers Symposium.

In the retrospective study, researchers examined 139 patients with pancreatic cancer treated at high-volume centers and 106 patients treated in a community medical center. Patients at the high-volume center had a median survival of 44 months, with a 39% 5-year survival rate, whereas patients treated in a community medical center had a median survival of 28 months, with a 25% 5-year survival rate.

Improvements in survival experienced by patients with pancreatic cancer treated with adjuvant chemotherapy at high-volume centers compared with community practices could be related to the ability to provide multidisciplinary care, James L. Abbruzzese, MD, said during the meeting.

“If we accept the results of the respective study, then there are two possible explanations. Volume is obviously one, but I am going to try to suggest that there are other factors that are at least as important or even more important,” said Abbruzzese, professor of Medicine, associate director of Clinical Research and Training, Duke University.

In an interview with OncLive, Abbruzzese discusses the underlying disparity between high-volume centers and community medical centers.

OncLive: Why do high-volume centers have better outcomes for patients with pancreatic cancer?

Abbruzzese: The session was geared around some data that was presented at the meeting suggesting that patients who received adjuvant chemotherapy after pancreatic resection had better outcomes if they received their chemotherapy through a high-volume center versus out in the community. It was a retrospective study, which I think controlled for all the factors that they could control for, but the fact that it is retrospective means that it's difficult to ascribe all of the differences that were seen to the fact that patients were treated at a high-volume center.

The bottom line of the abstract was that patients had better outcomes if they were treated at the high-volume center. The question then is, "Why would that be the case?" It's known that with respect to surgery, the higher the volume of surgery that a surgeon performs, the better overall outcomes there generally is. That has been demonstrated in numerous studies. What's not really understood is whether other elements of care, like chemotherapy, are better delivered in a high-volume center as well. If that's the case, then why is that so?

I represented, on a panel discussion, the viewpoint of the larger academic center, and I think the reason for the positive outcome for the abstract that was presented probably has to do more with the processes and extensive number of physicians with different specialties that can be brought to these centers for patients with pancreatic cancer. This is compared to just volume alone for the positive outcome.

What an academic center provides for patients is that they have ready access to individuals with expertise in surgery, radiation oncologists, medical oncologists, nutritionists, gastroenterologists, and so on. All of the elements that are required to take optimal care of the patients are centered in one place. It makes it very convenient for patients.

It also means that the people who are typically working closely together, working in multidisciplinary groups and doing research together, are together. I think these are the process issues that relate to the better outcomes seen at the larger centers.

I don't think there were any strong arguments against that feeling either, but there are other competing issues for patients. Cost is one major issue, as is the need to travel, especially for older patients or for individuals that for logistical and cost reasons cannot travel to a major center for multidisciplinary care.

The challenge we discussed, especially toward the end of the presentation, is if there are any other approaches that would be able to bring the specialty care out to the patients in a way that achieves the good outcomes seen, but without having the patient actually, physically travel to a high-volume center.

What are some of the challenges for the high-volume, multidisciplinary centers?

The biggest one, and this also came up toward the end of the session, is the economics around that. How does an academic center maintain its economic viability in an increasingly cost-aware, value-aware system?


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x